FCA
CRSP icon

FinTrust Capital Advisors’s CRISPR Therapeutics CRSP Stock Holding History

FinTrust Capital Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,400
Closed -$34K – 1142
2020
Q2 		$34K Buy
+3,400
New +$199K 0.01% 548

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

FinTrust Capital Advisors's CRSP Position: Q3 2024 in Review

FinTrust Capital Advisors held its CRISPR Therapeutics (CRSP) position steady in Q3 2024 at 180 shares worth $8.46K. The position accounts for ﹤0.01% of the portfolio, ranked #977.

FinTrust Capital Advisors first reported a position in CRSP in Q3 2019 and has held it in 21 quarters since. The position peaked at $4.21M in Q2 2021. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • FinTrust Capital Advisors held 180 shares of CRISPR Therapeutics worth $8.46K as of Q3 2024.
  • FinTrust Capital Advisors left its CRISPR Therapeutics share count unchanged in Q3 2024.
  • CRISPR Therapeutics made up ﹤0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #977 holding.
  • FinTrust Capital Advisors first reported a position in CRISPR Therapeutics in Q3 2019 and has held it in 21 quarters since.
  • FinTrust Capital Advisors's CRISPR Therapeutics position peaked at $4.21M in Q2 2021.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.